0904 GMT July 15, 2018
Despite improved clinical outcomes, patients live with extensive cognitive and physical delays resulting from toxicities associated with chemotherapy and radiation, medicalxpress.com reported.
Dr. Tamra Werbowetski-Ogilvie, Canada Research Chair in Neuro-oncology and Human Stem Cells and associate professor, biochemistry and medical genetics, Max Rady College of Medicine at the University of Manitoba said, "Better, more targeted and less toxic therapies are desperately needed to enhance survival as well as the quality of life for those children who live long term. Our work represents an important step towards this goal.”
A new study, published in Cancer Research, by Lisa Liang, PhD candidate at the U of M, Werbowetski-Ogilvie and Dr. Vijay Ramaswamy at Sick Kids Hospital, has identified a marker CD271 on the surface of the ‘brain tumor stem cells’ that could be used as a novel diagnostic tool for Sonic Hedgehog medulloblastoma tumors, one variant of medulloblastoma, the most common malignant primary pediatric brain tumor.
Werbowetski-Ogilvie's lab in the regenerative medicine program in the Max Rady College of Medicine, Rady Faculty of Health Sciences, also discovered that cells bearing this ‘CD271 mark’ appear to be targeted and killed with a drug named selumetinib.
She said, "This is a promising drug because it crosses the blood brain barrier, meaning it can actually get to the tumor, and is currently in clinical trials for treatment of other pediatric brain tumors.”
Her team has now moved into testing selumetinib in combination with other cancer-fighting drugs in a dish and in pre-clinical animal models with the long-term goal of increasing survival and enhancing the quality of life for those children who survive long term by de-escalating current cytotoxic therapies.